UPDATE 1-Aeterna to advance cancer trial after European nod

* To complete Phase 2 study later this year

* Received similar U.S. designation earlier

TORONTO, May 17 (BestGrowthStock) – Aeterna Zentaris (AEZ.TO: ) said
on Monday that it would complete a mid-stage European study for
its AEZS-108 compound later this year after the ovarian cancer
treatment received a key recommendation from European
regulators.

The Quebec City-based company, known for its cancer
treatments, said the Committee for Orphan Medicinal Products of
the European Medicines Agency granted the treatment orphan
medicinal product designation.

This designation provides special consideration to a
treatment intended for life-threatening conditions affecting
not more than five in 10,000 persons in a given area.

Earlier this month, the U.S. Food and Drug Administration
granted the ovarian cancer treatment orphan-drug status.

Stock Market Research Tools

($1=$1.03 Canadian)
(Reporting by Scott Anderson, editing by Dave Zimmerman)

UPDATE 1-Aeterna to advance cancer trial after European nod